TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Go here to read the rest:
Spectral Announces Second Quarter Results and Provides Corporate Update

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan

Go here to see the original:
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022.

Read the rest here:
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023

Here is the original post:
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022.

See the rest here:
VYNE Therapeutics Reports Second Quarter 2022 Financial Results

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022

More:
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.

Original post:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release

View post:
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval

Read more:
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine...

Conference call begins at 11:00 a.m. Eastern time today

Read the original:
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update